New Approaches for the Treatment of Genomic Damage in End-Stage Renal Disease

Journal of Renal Nutrition

Volumn 18, Issue 1, 2008, Pages 127-133

  Schupp, Nicole ^a   Schmid, Ursula ^a   Heidland, August ^a   Stopper, Helga ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; DNA DAMAGE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPHOCYTE; MICRONUCLEUS TEST; NEOPLASM; PHYSIOLOGY; REFERENCE VALUE; RENAL REPLACEMENT THERAPY;

CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DNA DAMAGE; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; LYMPHOCYTES; MICRONUCLEUS TESTS; NEOPLASMS; REFERENCE VALUES; RENAL DIALYSIS;

ANIMALIA;

EID: 37049035302     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2007.10.026     Document Type: Article

References (54)

1. Cheung A.K., Sarnak M.J., Yan G., et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 65 (2004) 2380-2389
2. Maisonneuve P., Agodoa L., Gellert R., et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354 (1999) 93-99
3. Stewart J.H., Buccianti G., Agodoa L., et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 14 (2003) 197-207
4. Teschner M., Garte C., Ruckle-Lanz H., et al. [Incidence and spectrum of malignant disease among dialysis patients in North Bavaria]. Dtsch Med Wochenschr 127 (2002) 2497-2502
5. Stopper H., Boullay F., Heidland A., et al. Comet-assay analysis identifies genomic damage in lymphocytes of uremic patients. Am J Kidney Dis 38 (2001) 296-301
6. Kan E., Undeger U., Bali M., et al. Assessment of DNA strand breakage by the alkaline COMET assay in dialysis patients and the role of Vitamin E supplementation. Mutat Res 520 (2002) 151-159
7. Fragedaki E., Nebel M., Schupp N., et al. Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis. Nephrol Dial Transplant (2005)
8. Stopper H., Meysen T., Bockenforde A., et al. Increased genomic damage in lymphocytes of patients before and after long-term maintenance hemodialysis therapy. Am J Kidney Dis 34 (1999) 433-437
9. Cengiz K., Block A.M., Hossfeld D.K., et al. Sister chromatid exchange and chromosome abnormalities in uremic patients. Cancer genetics and cytogenetics 36 (1988) 55-67
10. Buemi M., Floccari F., Costa C., et al. Dialysis-related genotoxicity: sister chromatid exchanges and DNA lesions in T and B lymphocytes of uremic patients. Genomic damage in patients on hemodiafiltration. Blood Purif 24 (2006) 569-574
11. Lim P.S., Ma Y.S., Cheng Y.M., et al. Mitochondrial DNA mutations and oxidative damage in skeletal muscle of patients with chronic uremia. J Biomed Sci 9 (2002) 549-560
12. Liu C.S., Ko L.Y., Lim P.S., et al. Biomarkers of DNA damage in patients with end-stage renal disease: mitochondrial DNA mutation in hair follicles. Nephrol Dial Transplant 16 (2001) 561-565
13. Tarng D.C., Huang T.P., Wei Y.H., et al. 8-hydroxy-2'-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis 36 (2000) 934-944
14. Hagmar L., Stromberg U., Bonassi S., et al. Impact of types of lymphocyte chromosomal aberrations on human cancer risk: results from Nordic and Italian cohorts. Cancer Res 64 (2004) 2258-2263
15. Bonassi S., Znaor A., Ceppi M., et al. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis (2006)
16. Vamvakas S., Bahner U., and Heidland A. Cancer in end-stage renal disease: potential factors involved-editorial. Am J Nephrol 18 (1998) 89-95
17. Zevin D., Malachi T., Gafter U., et al. Impaired DNA repair in patients with end-stage renal disease and its improvement with hemodialysis. Miner Electrolyte Metab 17 (1991) 303-306
18. Morena M., Cristol J.P., Senecal L., et al. Oxidative stress in hemodialysis patients: is NADPH oxidase complex the culprit?. Kidney Int Suppl (2002) 109-114
19. Morena M., Delbosc S., Dupuy A.M., et al. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodialysis international 9 (2005) 37-46
20. Boure T., and Vanholder R. Biochemical and clinical evidence for uremic toxicity. Artif Organs 28 (2004) 248-253
21. Vanholder R., De Smet R., Glorieux G., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 63 (2003) 1934-1943
22. Halliwell B. Oxidative stress and cancer: have we moved forward?. Biochem J 401 (2007) 1-11
23. Croteau D.L., and Bohr V.A. Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells. J Biol Chem 272 (1997) 25409-25412
24. Munch G., Keis R., Wessels A., et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 35 (1997) 669-677
25. Williams A.W., Chebrolu S.B., Ing T.S., et al. Early clinical, quality-of-life, and biochemical changes of "daily hemodialysis" (6 dialyses per week). Am J Kidney Dis 43 (2004) 90-102
26. Floridi A., Antolini F., Galli F., et al. Daily haemodialysis improves indices of protein glycation. Nephrol Dial Transplant 17 (2002) 871-878
27. Rocco M.V. More frequent hemodialysis: back to the future?. Advances in chronic kidney disease 14 (2007) e1-e9
28. Schleicher E.D., Bierhaus A., Haring H.U., et al. Chemistry and pathobiology of advanced glycation end products. Contrib Nephrol (2001) 1-9
29. Schwenger V., Zeier M., Henle T., et al. Advanced glycation endproducts (AGEs) as uremic toxins. Nahrung 45 (2001) 172-176
30. Bierhaus A., Hofmann M.A., Ziegler R., et al. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37 (1998) 586-600
31. Yamagishi S., Takeuchi M., Inagaki Y., et al. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 23 (2003) 129-134
32. Ceriello A., Mercuri F., Quagliaro L., et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 44 (2001) 834-838
33. Himmelfarb J., Stenvinkel P., Ikizler T.A., et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62 (2002) 1524-1538
34. Stopper H., Schinzel R., Sebekova K., et al. Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett 190 (2003) 151-156
35. Anantharaman P., and Moss A.H. Should the medicare ESRD program pay for daily dialysis? An ethical analysis. Advances in chronic kidney disease 14 (2007) 290-296
36. Hammes H.P., Du X., Edelstein D., et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9 (2003) 294-299
37. Pomero F., Molinar Min A., La Selva M., et al. Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetol 38 (2001) 135-138
38. Haupt E., Ledermann H., and Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy-a three-week randomized, controlled pilot study (BEDIP study). International journal of clinical pharmacology and therapeutics 43 (2005) 71-77
39. Winkler G., Pal B., Nagybeganyi E., et al. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittel-Forschung 49 (1999) 220-224
40. Frank T., Bitsch R., Maiwald J., et al. High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis patients by oral administration of benfontiamine. European journal of clinical pharmacology 56 (2000) 251-257
41. Carey R.M., and Siragy H.M. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24 (2003) 261-271
42. MacKenzie S.M., Fraser R., Connell J.M., et al. Local renin-angiotensin systems and their interactions with extra-adrenal corticosteroid production. J Renin Angiotensin Aldosterone Syst 3 (2002) 214-221
43. Smith G.R., and Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond) 1 (2004) 3
44. Kaschina E., and Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 12 (2003) 70-88
45. Deshayes F., and Nahmias C. Angiotensin receptors: a new role in cancer?. Trends Endocrinol Metab 16 (2005) 293-299
46. Hannken T., Schroeder R., Stahl R.A., et al. Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int 54 (1998) 1923-1933
47. Schupp N., Schmid U., Rutkowski P., et al. Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am J Physiol Renal Physiol 292 (2007) F1427-F1434
48. Gavras I., and Gavras H. Angiotensin II as a cardiovascular risk factor. J Hum Hypertens 16 Suppl 2 (2002) S2-S6
49. Touyz R.M. Reactive oxygen species and angiotensin II signaling in vascular cells - implications in cardiovascular disease. Braz J Med Biol Res 37 (2004) 1263-1273
50. Sadoshima J. Cytokine actions of angiotensin II. Circ Res 86 (2000) 1187-1189
51. Toto R.D. Treatment of hypertension in chronic kidney disease. Semin Nephrol 25 (2005) 435-439
52. Grossman E., Messerli F.H., Boyko V., et al. Is there an association between hypertension and cancer mortality?. Am J Med 112 (2002) 479-486
53. Friis S., Sorensen H.T., Mellemkjaer L., et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92 (2001) 2462-2470
54. Moore L.E., Wilson R.T., and Campleman S.L. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest 23 (2005) 240-255